MedWallet: Digital Solution for DMD Gene Therapy (Delandistrogene Moxeparvovec) Monitoring and Patient Support in Brazil

Topic:

Other

Poster Number: 41 S

Author(s):

FELIPE FRANCO DA GRACA, MD, Universidade Estadual de Campinas (UNICAMP), LEANDRA CREPALDI, ROCHE QUIMICOS E FARMACÊUTICOS SA BRASIL , SÃO PAULO, SP, Brasil, VIVIANE PINTO, ROCHE QUIMICOS E FARMACÊUTICOS SA BRASIL , SÃO PAULO, SP, Brasil, CRISTIANE CARVALHO, ROCHE QUIMICOS E FARMACÊUTICOS SA BRASIL , SÃO PAULO, SP, Brasil, JOSÉ FERROLI, ROCHE PHARMA SCHWEIZ, SWITZERLAND, Switzerland, CARLOS LIGUORI, ROCHE QUIMICOS E FARMACÊUTICOS SA BRASIL , SÃO PAULO, SP, Brasil, Clara Gontijo Camelo, MD, PhD, University of Sao Paulo, Isabela Baptista, Roche Químicos e Farmacêuticos S.A., São Paulo, SP, Brazil, Elian Rodrigues, Roche Químicos e Farmacêuticos S.A., São Paulo, SP, Brazil, Mahieddine CHETTOUH, ROCHE PHARMA SCHWEIZ, SWITZERLAND, Switzerland, Luana Souto Barros, PT, PhD, Roche Químicos e Farmacêuticos S.A., São Paulo, SP, Brazil

Objective: Gene therapy (delandistrogene moxeparvovec) for Duchenne Muscular Dystrophy (DMD) mandates rigorous post-infusion monitoring. This poster aims to present MedWallet, a digital solution adapted to the Brazilian context: an ecosystem integrating a patient-centric Mobile App and a Medical Web Portal, developed to support safety monitoring and clinical data management.
Methods: This is a descriptive study regarding the adaptation process of the global MedWallet digital platform (Development and Intellectual Property of F. Hoffmann-La Roche Ltd.). The process involved two steps: customizing the App with a patient-centric focus and developing an exclusive Web Portal for healthcare professionals. These steps were informed by qualitative interviews with two experts in the DMD patient journey to identify specific post-infusion monitoring needs
Results: Developed throughout 2024 (App) and 2025 (Web Portal), the solution synchronizes both interfaces. The App supports patients and caregivers with multimedia educational content, tracking safety tests, and emergency cards; the Web Portal functions as an electronic health record for clinical management. Patient-authorized bidirectional sharing enables physicians to input test results and monitor adherence to the critical 90-day safety schedule in real-time. Data is encrypted on the App’s servers and accessed only by the patient and authorized professionals. Since its implementation (June 2025), the system has enrolled 11 out of 16 eligible patients. Feedback was unanimously positive regarding ease of access and the tool’s impact on organizing the therapeutic journey and centralizing medical history.
Conclusion: MedWallet stands as an innovative digital solution with the potential to enhance post-infusion monitoring of gene therapy (delandistrogene moxeparvovec). By combining patient empowerment through the application with a web-based medical management tool, the solution promotes easy access to essential information, thereby supporting safety and adherence to treatment. Future studies involving quantitative analyses are required to measure its impact on care adherence and disease/therapy understanding among patients and caregivers.